Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)
Year: 2017
Type: article
Source: Annals of Oncology
Institutions: Queen Mary University of London, Barts Cancer Institute, Memorial Sloan Kettering Cancer Center, Duke Medical Center, Duke Cancer Institute, The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, Brigham and Women's Hospital, Exelixis (United States), Institut Gustave Roussy, Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2764128276